Previous 10 | Next 10 |
Vanda Pharmaceuticals Announces Participation at November 2023 Investor Conferences PR Newswire WASHINGTON , Nov. 9, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA ) today announced that the company will participate in the following upc...
2023-11-08 21:36:04 ET Vanda Pharmaceuticals Inc. (VNDA) Q3 2023 Results Conference Call November 08, 2023 04:30 PM ET Company Participants Kevin Moran - SVP, CFO and Treasurer Dr. Mihael Polymeropoulos - President, CEO and Chairman Tim Williams - General Counsel...
2023-11-08 16:07:14 ET More on Vanda Pharmaceuticals Vanda Pharmaceuticals: Value In The Biotech Space Seeking Alpha’s Quant Rating on Vanda Pharmaceuticals Historical earnings data for Vanda Pharmaceuticals Financial information for Vanda Pharmaceutic...
Vanda Pharmaceuticals Reports Third Quarter 2023 Financial Results PR Newswire Total revenues in the first nine months of 2023 were $147.4 million Vanda provides update on pipeline advancements and regulatory plans WASHINGTON , Nov. 8, 2023 /P...
Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...
Vanda Pharmaceuticals to Announce Third Quarter 2023 Financial Results on November 8, 2023 PR Newswire Conference Call and Webcast to Follow WASHINGTON , Nov. 1, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it wil...
Hitachi Construction Machinery Co. Ltd ADR (HTCMY) is expected to report for Q2 2024 DigitalBridge Group Inc. (DBRG) is expected to report $0 for Q3 2023 LY Corp ADR (YAHOY) is expected to report for Q2 2024 DT Midstream Inc. (DTM) is expected to report $0.9 for Q3 2023 Summit Mat...
Vanda Pharmaceuticals Inc. (VNDA) is expected to report $-0.04 for Q3 2023
Vanda Pharmaceuticals Intends to Petition the U.S. Supreme Court in its HETLIOZ® ANDA Litigation PR Newswire WASHINGTON , Oct. 20, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced its intention to file a petition for a w...
2023-10-16 18:17:50 ET Summary Vanda Pharmaceuticals (VNDA) is a net-net opportunity with a market cap of $250mm and $387mm in net cash. The market is worried about declining sales of the company's top drug. Despite the challenges, VNDA has multiple positive catalysts on the h...
News, Short Squeeze, Breakout and More Instantly...
Vanda Pharmaceuticals Inc. Company Name:
VNDA Stock Symbol:
NASDAQ Market:
Vanda Pharmaceuticals Inc. Website:
2024-07-17 04:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-11 07:00:07 ET Charles Duncan from Cantor Fitzgerald issued a price target of $11.00 for VNDA on 2024-07-11 06:12:00. The adjusted price target was set to $11.00. At the time of the announcement, VNDA was trading at $5.21. VNDA currently trades -22.96% versus its...
Federal Court Allows Vanda's HETLIOZ® Patent Lawsuit to Proceed against Teva and Apotex PR Newswire WASHINGTON , July 1, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. District Court for the District of ...